Please login to the form below

Not currently logged in

Novartis sales dip, but all eyes are on Entresto

Newheart failure drug could return the company to growth


Exchange rates and weak eyecare sales held back Novartis' revenues in the second quarter, but analysts expect new heart failure drug Entresto to set the company back on the growth track.

Group sales fell 5% to $12.7bn in the quarter, with the pharma division also slipping back around 4% to $7.8bn on the back of generic competition for high blood pressure drug Diovan (valsartan) and other products such as its oestrogen patch Vivelle-Dot.

The forthcoming US launch of Entresto (valsartan and sacubitril) is predicted to drive upwards momentum for the pharma division in the coming months as it starts its trajectory towards what some analysts believe will be peak sales of around $5bn.

Novartis' decision to set the drug's price a little higher than expected - at $12.50 per day - has not generated any tangible resistance in the US, according to chief executive Joe Jimenez, who said the company expects steady take-up of the product in the coming months and an acceleration in 2016.

Meanwhile, there were other bright spots in Novartis' pharma portfolio, including oral multiple sclerosis therapy Gilenya (fingolimod) which grew 26% to $700m in the quarter and leukaemia therapy Tasigna (nilotinib), up 21% to $412m.  

Tasigna is a key product for Novartis as it is the follow-up to big seller Glivec (imatinib), which is facing the threat of generic competition outside the US. Sales of the drug - which remains Novartis' top product - dipped 1% to $1.18bn in the quarter.

Cancer drug Afinitor (everolimus) also put in a good performance - up 19% to $423m - although the product is likely to come under pressure from newer cancer agents such as Bristol-Myers Squibb's Opdivo, which has just outperformed it in a kidney cancer trial. 

In its respiratory portfolio, Novartis said long-acting muscarinic antagonist/long-acting beta agonist (LAMA/LABA) product Ultibro (indacaterol and glycopyrronium bromide) added $66m to its coffers, three times the sales recorded in the same period of 2014. 

Pharma chief David Epstein said the drug is outperforming competitors in markets where other LAMA/LABA combinations been launched, according to data from IMS. It competes with drugs such as GlaxoSmithKline's Anoro (umeclidinium bromide and vilanterol) and Boehringer Ingelheim's just approved Spiolto (tiotropium and olodaterol).

Novartis said it is also encouraged by a strong performance in its generics division Sandoz, with overall sales up 11% and biosimilar turnover up 57%. The division also has a new growth driver in the form of Glatopa, its recently-approved generic of Teva's MS blockbuster Copaxone (glatiramer acetate).

Jimenez said: "Novartis had a strong quarter for innovation, with US approval and launch of both Entresto and Glatopa being key highlights. We are confident we will deliver on our priorities for the year, and confirm our full-year guidance."

For 2015 as a whole, the company is predicting a sales increase in the mid-single digits, with operating income rising in the high-single-digit range.

Article by
Phil Taylor

21st July 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...